Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;18(6):455-463.
doi: 10.1080/14740338.2019.1617847. Epub 2019 May 17.

Drug Safety Evaluation of Aripiprazole in Bipolar Disorder


Drug Safety Evaluation of Aripiprazole in Bipolar Disorder

Alessandro Cuomo et al. Expert Opin Drug Saf. .


Introduction: Safety and tolerability of medications are key variables to inform treatment choice for patients with bipolar disorder (BD). This review focuses on the overall tolerability and safety profile of aripiprazole when used for its bipolar disorder indications, which include acute treatment of manic and mixed episodes and maintenance treatment of bipolar I disorder for the oral formulation, agitation associated with bipolar mania for the injectable immediate-release formulation, and maintenance treatment of bipolar I disorder for the long acting once-monthly (AOM) formulation. Areas covered: The authors reviewed aripiprazole safety in bipolar disorder according to product labeling. English language reports located through PubMed and information available on the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) websites, with a focus on the safety and tolerability of aripiprazole, were reviewed. Expert opinion: Compared to many other antipsychotics, aripiprazole has a relatively favorable tolerability profile, with a lower risk for weight gain, dyslipidemia, diabetes, and hyperprolactinemia. Compared to first-generation antipsychotics, and similar to most second-generation antipsychotics, aripiprazole has a reduced propensity for extrapyramidal side effects and a better cardiovascular safety.

Keywords: Aripiprazole; bipolar; dyskinesia; long acting; metabolic; pregnancy; prolactin; safety; tolerability; weight.

Similar articles

See all similar articles

Cited by 2 articles

MeSH terms